View Single Post
Old 04-13-2011, 11:50 PM   #4
radiant
Senior Member
 
Join Date: Oct 2008
Posts: 88
Re: possible progress in prevention of brain mets w mTor inhibitor & MEK inhibitor co

gdpawel:


>>These results, though exploratory, suggest a superior approach for drug development, allowing the lab to identify important leads much faster than the clinical trial process.<<
---------------
This sounds very encouraging, but how can they do this? I"m gleaning from your post that you are saying cancer researchers, and specifically folks at Rational Therapeutics, are discovering specific targets to go after to stop cancer from spreading. And, now they can test ways to supress these cancer targets this w/out having to go through a clinical trial process? That's amazing.
I'm guessing what you are saying is now they can perform more research in the lab, instead of having to do beginning research at this level on cancer patients in clinical trials? Is that what you are saying.
I'm not good at understanding the detailed clinical language.
Thanks for your help!
Kim
__________________
------------------------------
Dx Stage 3C 2005, triple +, tons of lymph nodes as well. FEC, surgery, TCH, rads, herceptin 1 year. And, Aromasin.
2007 - recurrence to medistinal lymph node, Abraxene and Herceptin - took it down 50%
2008 - on Arimidex/Herceptin - stable lymph node.
2009 - stable on Arimidex/Herceptin
2010 - lymph node progression and liver mets.
2010 - went on Gemzar, Navelbine, Herceptin - Navelbine and Herceptin took liver mets down. lymph node slightly progressed.
2010 - did Xeloda & Tykerb - MAJOR progression in liver in only 6 weeks.
Dec 2010 - present - Ixempra/Avastin/Herceptin/Fasoldex - regressing
June 2012 - chemo break
Sept 19, 2012 - start t-dm1. Chose this over going back on Ixempra.
radiant is offline   Reply With Quote